Enhancing tumor specific immune responses by transcutaneous vaccination.

Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that are involved to varying degrees in the induction of robust immune responses. Transcutaneous administration of cancer vaccines may therefore harness the immune potential of these DCs, however, this approach is hampered by the impermeability of the stratum corneum. Innovative vaccine formulations including various nanoparticles, such as liposomes, are therefore needed to properly deliver cancer vaccine components to skin DCs. Areas covered: The recent insights into skin DC subsets and their functional specialization, the potential of nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. Expert commentary: To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune responses, investigation of the cellular and molecular interplay that controls tumor progression should be pursued in parallel with clinical development. The resulting knowledge will then be translated into improved cancer vaccines that better target the most appropriate immune players.journal articlereviewresearch support, non-u.s. gov't2017 11importe

Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification:

BACKGROUND: Over the last few decades, new synthetic insulin analogues have been developed. Their measurement is of prime importance in the investigation of hypoglycaemia, but their quantification is hampered by variable cross-reactivity with many insulin assays. For clinical analysis, it has now become essential to know the potential cross-reactivity of analogues of interest. METHODS: In this work, we performed an extensive study of insulin analogue cross-reactivity using numerous human insulin immunoassays. We investigated the cross-reactivity of five analogues (lispro, aspart, glulisine, glargine, detemir) and two glargine metabolites (M1 and M2) with 16 commercial human insulin immunoassays as a function of concentration. RESULTS: The cross-reactivity values for insulin analogues or glargine metabolites ranged from 0% to 264%. Four assays were more specific to human insulin, resulting in negligible cross-reactivity with the analogues. However, none of the 16 assays was completely free of cross-reactivity with analogues or metabolites. The results show that analogue cross-reactivity, which varies to a large degree, is far from negligible, and should not be overlooked in clinical investigations. CONCLUSIONS: This study has established the cross-reactivity of five insulin analogues and two glargine metabolites using 16 immunoassays to facilitate the choice of the immunoassay(s) and to provide sensitive and specific analyses in clinical routine or investigation

Mise au point d'une formulation de liposomes présentant le peptide mart dans le but de traiter le mélanome par voie vaccinale

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Conception et évaluation biologique de liposomes chargés en agonistes de NOD1 pour la vaccination anti-tumorale

Résumé françaisSTRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Mise au point de formulations peptidiques en vue d'un ciblage actif des cellules infectées par HPV

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Conception et caractérisation d'un vaccin antitumoral à base de liposomes (application à la vaccination contre le cancer du poumon)

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Conception et caractérisation de liposomes ultra-déformables (application à la vaccination anti-tumorale par voie transdermique)

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

La vaccination par voie nasale (conception et caractérisation de liposomes mucoadhésifs)

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Développement de formulations vaccinales synthétiques à base de liposomes contre Pseudomonas aeruginosa

STRASBOURG ILLKIRCH-Pharmacie (672182101) / SudocSudocFranceF

Développement d'un procédé de préparation d'une nouvelle génération de nanocapsules lipidiques

CHATENAY M.-PARIS 11-BU Pharma. (920192101) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF